![Western Blot: WDR5 Antibody [NBP3-18669] - Figure 3. Western blot analysis using the antibody directed against WDR5 Nclear extracts from HeLa cells (20 ug) were analysed by Western blot using the antibody against WDR5 diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.](http://images.novusbio.com/fullsize/WDR5-Antibody-Western-Blot-NBP3-18669-img0001.jpg "Western Blot: WDR5 Antibody [NBP3-18669] - Figure 3. Western blot analysis using the antibody directed against WDR5 Nclear extracts from HeLa cells (20 ug) were analysed by Western blot using the antibody against WDR5 diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, ICC/IF, IHC, ChIP |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 2 mg/ml |
| Immunogen | Polyclonal antibody raised in rabbit against human WDR5 (WD (tryptophan-aspartate) repeat domain 5), using a recombinant protein. |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | WDR5 |
| Purity | Protein G purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
| Application Notes | Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-5 ug per ChIP. |
| Storage | Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS |
| Preservative | 0.05% Sodium Azide and 0.05% ProClin 300 |
| Concentration | 2 mg/ml |
| Purity | Protein G purified |
![Immunocytochemistry Osteopontin/OPN Antibody [Unconjugated]](https://images.novusbio.com/images2/Osteopontin_AF808_Immunocytochemistry__Immunofluorescence_23325.jpg)
![Neutralization Osteopontin/OPN Antibody [Unconjugated]](https://images.novusbio.com/images2/Osteopontin_AF808_Block_Neutralize_8975.jpg)
![Immunohistochemistry Osteopontin/OPN Antibody [Unconjugated]](https://images.novusbio.com/images2/Osteopontin_AF808_Immunohistochemistry_9333.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for WDR5 Antibody (NBP3-18669)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunocytochemistry/Immunofluorescence: WDR5 Antibody [NBP3-18669] - Figure 4. Immunofluorescence using the antibody directed against WDR HeLa cells were stained with the antibody against WDR5 and with DAPI. Cells were fixed with 4% formaldehyde for 10 and blocked with PBS/TX-100 containing 5% normal goat serum and 1% BSA. The cells were immunofluorescently labeled with the WDR5 antibody (left) diluted 1:1,000 in blocking solution followed by an anti-rabbit antibody conjugated to Alexa488. The middle panel shows staining of the nuclei with DAPI. A merge of the two stainings is shown on the right.](http://images.novusbio.com/fullsize/WDR5 Antibody-Immunocytochemistry-Immunofluorescence-NBP3-18669-img0003.jpg "Immunocytochemistry/Immunofluorescence: WDR5 Antibody [NBP3-18669] - Figure 4. Immunofluorescence using the antibody directed against WDR HeLa cells were stained with the antibody against WDR5 and with DAPI. Cells were fixed with 4% formaldehyde for 10 and blocked with PBS/TX-100 containing 5% normal goat serum and 1% BSA. The cells were immunofluorescently labeled with the WDR5 antibody (left) diluted 1:1,000 in blocking solution followed by an anti-rabbit antibody conjugated to Alexa488. The middle panel shows staining of the nuclei with DAPI. A merge of the two stainings is shown on the right.")
![Chromatin Immunoprecipitation (ChIP): WDR5 Antibody [NBP3-18669] - Figure 1. ChIP results obtained with antibody directed against WDR5. ChIP assays performed using HeLa cells, antibody against WDR5 and optimized PCR primer sets for qPCR. ChIP performed with the](http://images.novusbio.com/fullsize/WDR5-Antibody-Chromatin-Immunoprecipitation-ChIP-NBP3-18669-img0004.jpg "Chromatin Immunoprecipitation (ChIP): WDR5 Antibody [NBP3-18669] - Figure 1. ChIP results obtained with antibody directed against WDR5. ChIP assays performed using HeLa cells, antibody against WDR5 and optimized PCR primer sets for qPCR. ChIP performed with the")
![Chromatin Immunoprecipitation Sequencing: WDR5 Antibody [NBP3-18669] - Figure 2. ChIP-seq results obtained with the antibody directed against WDR5 ChIP was performed on sheared chromatin from 4 million HeLa cells using 2 ug of the antibody against WDR5 as described above. The IPd DNA was subsequently analysed on an Illumina HiSeq. Library preparation, cluster generation and sequencing were performed according to the manufacturers instructions. The 50 bp tags were aligned to the human genome using the BWA algorithm. Figure 2 shows the enrichment along the complete sequence and a 2 Mb region of human chromosome 1 (fig 2A and B), and in two genomic regions surrounding the RPL41 and RPS4X positive control genes (fig 2C and D).](http://images.novusbio.com/fullsize/WDR5-Antibody-Chromatin-Immunoprecipitation-Sequencing-NBP3-18669-img0002.jpg "Chromatin Immunoprecipitation Sequencing: WDR5 Antibody [NBP3-18669] - Figure 2. ChIP-seq results obtained with the antibody directed against WDR5 ChIP was performed on sheared chromatin from 4 million HeLa cells using 2 ug of the antibody against WDR5 as described above. The IPd DNA was subsequently analysed on an Illumina HiSeq. Library preparation, cluster generation and sequencing were performed according to the manufacturers instructions. The 50 bp tags were aligned to the human genome using the BWA algorithm. Figure 2 shows the enrichment along the complete sequence and a 2 Mb region of human chromosome 1 (fig 2A and B), and in two genomic regions surrounding the RPL41 and RPS4X positive control genes (fig 2C and D).")
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Western Blot ASCL2/Mash2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ASCL2_AF6539_Western_Blot_10231.jpg)
![Immunohistochemistry ASCL2/Mash2 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af6539_human-ascl2-mash2-affinity-purified-polyclonal-ab-immunohistochemistry-1262023144847.jpg)
![Immunocytochemistry RUNX2/CBFA1 Antibody (232902) [Unconjugated]](https://images.novusbio.com/images2/RUNX2_MAB2006_Immunocytochemistry_13309.jpg)
![Chromatin Immunoprecipitation (ChIP) Oct-3/4 Antibody [Unconjugated]](https://images.novusbio.com/images2/Oct-3_4_AF1759_Chromatin_Immunoprecipitation_11218.jpg)
![Immunocytochemistry Oct-3/4 Antibody [Unconjugated]](https://images.novusbio.com/images2/Oct-3_4_AF1759_Immunocytochemistry_7093.jpg)
![Simple Western Oct-3/4 Antibody [Unconjugated]](https://images.novusbio.com/images2/Oct3_4_AF1759_Simple_Western_20183.jpg)
![Immunohistochemistry PITX2 Antibody [Unconjugated]](https://images.novusbio.com/images2/PITX2_AF7388_Immunohistochemistry_12162.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
